501 related articles for article (PubMed ID: 12458816)
1. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
Dilber E; Erduran E; Işik Y
Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
[TBL] [Abstract][Full Text] [Related]
2. Kala-azar associated with coombs-positive autoimmune hemolytic anemia in the patients coming from the endemic area of this disease and successful treatment of these patients with liposomal amphotericin B.
Erduran E; Bahadir A; Gedik Y
Pediatr Hematol Oncol; 2005; 22(5):349-55. PubMed ID: 16020124
[TBL] [Abstract][Full Text] [Related]
3. Treatment of visceral leishmaniasis.
Ozsoylu S
Turk J Pediatr; 2003; 45(3):280. PubMed ID: 14696814
[No Abstract] [Full Text] [Related]
4. Immune mediated hemolysis in visceral leishmaniasis.
Mahajan V; Marwaha RK
J Trop Pediatr; 2007 Aug; 53(4):284-6. PubMed ID: 17483492
[TBL] [Abstract][Full Text] [Related]
5. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
[TBL] [Abstract][Full Text] [Related]
7. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
[TBL] [Abstract][Full Text] [Related]
8. [First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France].
Minodier P; Robert S; Noël G; Blanc P; Retornaz K; Garnier JM
Arch Pediatr; 2005 Jul; 12(7):1102-8. PubMed ID: 15964525
[TBL] [Abstract][Full Text] [Related]
9. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
11. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
Vigna E; De Vivo A; Gentile M; Morelli R; Lucia E; Mazzone C; Recchia AG; Vianelli N; Morabito F
Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035
[TBL] [Abstract][Full Text] [Related]
14. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
Manfredi R; Marinacci G; Calza L; Passarini B
Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
[No Abstract] [Full Text] [Related]
15. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
16. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Meyerhoff A
Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
[TBL] [Abstract][Full Text] [Related]
17. [Importance of drug carriers in the treatment of visceral leishmaniasis].
Fusai T; Durand R; Boulard Y; Paul M; Bories C; Rivollet D; Houin R; Deniau M
Med Trop (Mars); 1995; 55(1):73-8. PubMed ID: 7637615
[TBL] [Abstract][Full Text] [Related]
18. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Berman JD
Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
[No Abstract] [Full Text] [Related]
19. Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children.
Apa H; Devrim İ; Bayram N; Deveci R; Demir-Özek G; Cartı ÖU
Turk J Pediatr; 2013; 55(4):378-83. PubMed ID: 24292030
[TBL] [Abstract][Full Text] [Related]
20. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]